ReviewEye (London, England)2023
Conjunctival Lymphoma.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Scleral perforation in a young adult with Burkitt lymphoma.BMJ case reports · 2026Article
- Imaging of Ocular Surface Lesions Using Anterior Segment Optical Coherence Tomography.Clinical & experimental ophthalmology · 2026Review
- Orbital atypical lymphocytic panniculitis preceding conjunctival marginal zone lymphoma in the same patient with undifferentiated connective tissue disease: a case-based review.Rheumatology international · 2025Review
- Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review.Seminars in ophthalmology · 2025Review
- Article
- Clinicopathological correlation of caruncular lesions: a 22-year report from the Middle East.BMC ophthalmology · 2025Article
- Can high-resolution optical coherence tomography provide an optical biopsy for ocular surface lesions?Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2025Review
- Incidence, clinical features, and survival outcomes of primary malignant conjunctival tumor: a US population-based retrospective cohort analysis based on the SEER database (1975-2018).Translational cancer research · 2025Article
- Article
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- The Dilemma for Early-Stage Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma: To Treat or Not to Treat?Journal of personalized medicine · 2024Article
- Spontaneous regression and rare relapse after excisional biopsy in long-term observation of 31 patients with primary conjunctival lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Prognostic Value ofKorean journal of radiology · 2024Article
- Article
- Conjunctival Marginal Zone Lymphoma in a Patient With Neurofibromatosis Type 1: A Case Report.Cureus · 2023Article
- Transcriptional Profiling Identifies Prognostic Gene Signatures for Conjunctival Extranodal Marginal Zone Lymphoma.Biomolecules · 2023Article
- The clinicopathological analysis of ocular and orbit tumors in southeast of China.Frontiers in oncology · 2023Article
- Conjunctival lymphoma: case report.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. Clinical manifestations are non-specific, but include unilateral or bilateral painless salmon-pink conjunctival lesions. Approaches to treatment have centered around local immunomodulation, often with Interferon-α2b or Rituximab (anti-CD20 monoclonal antibody) with or without radiation. Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians' ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In this paper, we review the classification, clinical features, diagnostic techniques, and emerging strategies for management and prognostication of conjunctival lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.